• Tessa Receives PRIME Designation from EMA for CD30 CAR-T Therapy americanpharmaceuticalreview
    January 27, 2021
    Tessa Therapeutics announced the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
PharmaSources Customer Service